SillaJen, Inc. (KOSDAQ:215600)
South Korea · Delayed Price · Currency is KRW 2,920.00
+85.00 (3.00%)
Aug 13, 2025, 3:30 PM KST
United States Steel Revenue
SillaJen had revenue of 1.16B KRW in the quarter ending March 31, 2025, with 282.86% growth. This brings the company's revenue in the last twelve months to 4.78B, up 38.78% year-over-year. In the year 2024, SillaJen had annual revenue of 3.93B, down -0.33%.
Revenue (ttm)
4.78B
Revenue Growth
+38.78%
P/S Ratio
81.90
Revenue / Employee
111.20M
Employees
37
Market Cap
391.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.93B | -12.90M | -0.33% |
| Dec 31, 2023 | 3.94B | -1.07B | -21.42% |
| Dec 31, 2022 | 5.01B | 4.76B | 1,870.95% |
| Dec 31, 2021 | 254.36M | -1.42B | -84.77% |
| Dec 31, 2020 | 1.67B | -7.40B | -81.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| Peptron | 4.30B |
| PharmaResearch | 392.31B |
| LigaChem Biosciences | 146.42B |